Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nicotine polacrilex + bupropion
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- Small Molecules
- Administration
- Oral, Buccal
01
Overview
This pharmacological combination consists of nicotine polacrilex, a nicotine replacement therapy (NRT), and bupropion, an atypical antidepressant. Nicotine polacrilex is a resin complex that delivers a controlled dose of nicotine to the systemic circulation via the buccal mucosa, acting as an agonist at nicotinic acetylcholine receptors to alleviate withdrawal symptoms. Bupropion functions as a norepinephrine-dopamine reuptake inhibitor (NDRI) and also acts as a non-competitive antagonist at neuronal nicotinic acetylcholine receptors. This dual action helps to reduce the urge to smoke and diminishes the reinforcing effects of nicotine. The combination was specifically evaluated by the University of California, San Francisco (UCSF) in clinical trials (such as NCT00086385) aimed at maintaining smoking cessation and preventing relapse in older adults (aged 50 and older) through extended pharmacological support and tailored counseling.
- Brand names
- NicoretteZybanWellbutrin
- Other names
- nicotine gum + bupropionnicotine replacement therapy + bupropionNRT + bupropion
02
Targets
DAT (Dopamine plasma membrane transport protein)Nicotinic Acetylcholine ReceptorNET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on nicotine polacrilex + bupropion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nicotine polacrilex + bupropion.